CLC bio acquires the drug discovery-software company Molegro
The acquisition of Molegro supports CLC bio's strategy of continuously expanding their bioinformatics offerings beyond Next Generation Sequencing, as well as in bioinformatics areas of value to their customer base.
In the coming years, CLC bio will invest significant resources into the continued development of the acquired protein-ligand docking and data modeling software. All existing Molegro customers with an active support and software upgrade contract have been transferred to CLC bio. Effective immediately, Molegro will become part of CLC bio's organization at their Aarhus, Denmark, headquarters. The financial terms of the transaction were not disclosed.
- CLC Genomics Workbench
- CLC Main Workbench
- General Information